GlassScriptPhysician profile
Amy S Holder
NPI 1619373362
$5,229.07
in general payments reported to CMS, 2019-2025
25 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $560 · 2022: $1,249 · 2023: $1,226 · 2024: $1,724 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $584.77 | 2021-2024 | Austedo Xr |
| Novo Nordisk INC | $555.22 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.27 | 2022-2024 | Jardiance |
| Corcept Therapeutics | $451.95 | 2023-2024 | Korlym |
| Abbvie INC. | $422.62 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.63 | 2021-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $290.36 | 2021-2024 | Tezspire |
| Sanofi-Aventis U.S. LLC | $257.87 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $125.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2024 | |
| Abbott Laboratories | $124.98 | 2024 | Freestyle Libre 3 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.98 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $122.91 | 2024 | Amvuttra |
| Takeda Pharmaceuticals U.S.A., INC. | $121.35 | 2025 | Gattex |
| Genzyme Corporation | $120.18 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $119.97 | 2023 | Accrufer |
| Rhythm Pharmaceuticals, INC. | $113.06 | 2021 | |
| Lilly USA, LLC | $107.34 | 2024 | Zepbound |
| Astellas Pharma US INC | $104.83 | 2023 | Veozah |
| Bioventus LLC | $93.87 | 2022 | |
| Tandem Diabetes Care, INC. | $84.95 | 2022 | |
| Paratek Pharmaceuticals, INC. | $83.33 | 2022 | |
| Dexcom, INC. | $79.31 | 2022 | |
| Medtronic, INC. | $78.63 | 2023 | Harmony |
| Ibsa Pharma INC. | $49.75 | 2023 | Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Holder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.